Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovar... (

Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer

Date:2/12/2009

- Discovery Could Lead to the Development of a Next-Generation Assay to Improve Diagnosis and Treatment of Ovarian Cancer -

FREMONT, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Vermillion, Inc. (OTC Bulletin Board: VRML), a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued a notice of allowance to the Company for the discovery of hepcidin as a biomarker for ovarian cancer. The discovery could ultimately lead to the development of an improved, next-generation assay that might provide physicians with additional, valuable information to diagnose ovarian cancer.

"The notice of issuance of this patent validates the strength of our approach in the development of innovative molecular diagnostics," said Eric T. Fung, M.D., Ph.D, Chief Scientific Officer of Vermillion and co-inventor. "This patent comprises an important component of our ovarian cancer patent portfolio."

The patent also covers the measurement of hepcidin by a variety of methods, including mass spectrometry and other immunoassay approaches.

About Vermillion's Ovarian Cancer Diagnostic Program

Vermillion has multiple ovarian cancer diagnostic tests in development. The most advanced of Vermillion's programs is the OVA1 test, which is designed to utilize a panel of biomarkers to help identify women with a higher likelihood of malignancy so they can be referred to a gynecologic oncologist for their initial surgery. Vermillion filed a 510(K) Application with the U.S. Food and Drug Administration for its OVA1(TM) Test in June 2008.

Additionally, studies are underway to develop tests with the capability of detecting early-stage ovarian cancer, predicting prognosis and recurrence, and identifying women considered at high-risk for the disease.

Vermillion's premier diagnostic development program is being conducted with several leading collaborators at T
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Vermillion Announces Receipt of NASDAQ Panel Decision
2. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
3. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
4. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
5. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
6. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
7. Vermillion Announces Appointment of John Hamilton to Board of Directors
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
10. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
11. Vermillion Announces Effectiveness of Reverse Stock Split

Post Your Comments:

Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovar...( - Discovery Could Lead to the Develop...)